生物技术公司Dyadic International, Inc. 与斯克里普斯研究所（Scripps Research）宣布建立合作关系，共同致力于开发针对汉坦病毒的快速响应抗体与疫苗。此项合作旨在结合双方在蛋白质表达平台与前沿免疫学研究方面的专长，以应对这一潜在致命病毒的公共卫生挑战。
汉坦病毒可引发出血热伴肾综合征等严重疾病，目前全球范围内仍缺乏广泛可用的高效预防与治疗手段。此次协作将利用Dyadic的创新型C1蛋白表达系统，旨在加速治疗性抗体与候选疫苗抗原的研发与生产进程。
通过整合斯克里普斯研究所在结构生物学与抗体发现领域的深厚积淀，该合作项目力求缩短从基础研究到临床前开发的时间周期。双方期望通过这一联合努力，为未来可能出现的汉坦病毒疫情构建更迅捷的医疗对策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.